Country: Canada
Language: English
Source: Health Canada
BENZOYL PEROXIDE; CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)
TARO PHARMACEUTICALS INC
D10AF51
CLINDAMYCIN, COMBINATIONS
5%; 1%
GEL
BENZOYL PEROXIDE 5%; CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1%
TOPICAL
45G
Prescription
ANTIBIOTICS
Active ingredient group (AIG) number: 0242561001; AHFS:
APPROVED
2015-04-22
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TARO-CLINDAMYCIN / BENZOYL PEROXIDE GEL clindamycin and benzoyl peroxide gel, 1%/5%, w/w (clindamycin as clindamycin phosphate) Topical Acne Therapy Professed Standard Taro Pharmaceuticals Inc. 130 East Drive, Brampton Ontario L6T 1C1 Date of Preparation: March 4, 2019 Submission Control No: 223918 Page 2 of 31 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION .................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 3 WARNINGS AND PRECAUTIONS.............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 6 DRUG INTERACTIONS ................................................................................................ 9 DOSAGE AND ADMINISTRATION .......................................................................... 10 OVERDOSAGE ............................................................................................................ 10 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 11 STORAGE AND STABILITY...................................................................................... 12 SPECIAL HANDLING INSTRUCTIONS ................................................................... 12 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................... 12 PART II: SCIENTIFIC INFORMATION ............................................................................. 14 PHARMACEUTICAL INFORMATION ..................................................................... 14 CLINICAL TRIALS ................................................... Read the complete document